H19 and heart failure: The H19 gene therapy prevents and reverses experimental pressure-overload-induced heart failure according to interaction with the polycomb repressive complex 2, suppressing H3K27 trimethylation, which, in turn, leads to reduced NFAT expression and activity (33).